Squamous cell carcinoma (SCC) is the second most common human skin cancer and the second leading cause of skin cancer-related death. Recently, a new compound, ingenol mebutate (IM), was approved for treatment of actinic keratosis (AK), a precursor of SCC. Since the mechanism of action is poorly understood, we have further investigated the mechanism of IM-induced cell death.
Raw data was processed in the programming environment R using the limma package (20) . The data were background corrected and quantile normalized. Pairwise comparison of treatment vs control samples was performed for each cell line. Differentially expressed genes were deemed to be significant if the absolute log-fold change was more than 2 and the FDR adjusted p-value was less than 0.05. Heat map was generated by hierarchical clustering and Euclidean distance was used for distance metric. Microarray data have been deposited in NCBI's Gene Expression Omnibus (21) in accordance with MIAME guidelines (GEO Series accession number GSE63308). Pathway analysis of deregulated genes was done using the software GeneGo (Thomson Reuters, Zug, Switzerland).
RNA isolation and qPCR
RNA from cells and tissue was isolated with TRIzol ® (Invitrogen, Basel, Switzerland) as described in the protocol. Reverse transcription was achieved using the Reverse Transcription Kit from Promega (Madison, WI, United States). qPCR was performed on the ViiA7 real time PCR machine (life technologies, Zug, Switzerland) using SYBR green mix (Roche, Basel, Switzerland). The following primers from Microsynth (Balgach, Switzerland) were used. 
Phosphoprotein array
PathScan ® Intracellular Signaling Array Kit from Cell Signaling (#7323) was used according to the manufacturer's instructions.
Drugs and inhibitors
Ingenol mebutate (Suppl. inhibitor SB203580 (Cell Signaling, #5633) was used at 250-500 nM. 12-O-Tetradecanoylphorbol-13-acetate (TPA) (Sigma, #P1585) and used at various concentrations as indicated in the results section.
Knock-down
For knock down of PKCδ, IL1R2, and IL13RA2, cells were transfected with INTERFERin ® (Polyplus transfections) and specific siRNAs (QIAgen, Hombrechtikon, Switzerland). 
Results

Ingenol mebutate inhibits viability and proliferation of keratinocytes and SCC cells
To investigate the impact of IM on epithelial cell viability and proliferation and to determine a working concentration for further experiments, we treated primary keratinocytes, patient-derived SCC cells, and SCC cell lines for 24h, 48h and 72h with IM in a range from 1 nM to 10 5 nM. All cell types showed a biphasic decrease in viability (Fig. 1A) and proliferation (Fig. 1B) 1A and 1B) . At a concentration of 10 5 nM, cells died to a great extent due to cytotoxicity. For further experiments we used a concentration of 100 nM, since this concentration had the largest effect at the first peak of the biphasic response.
To find out whether the biphasic effect was cell-type specific, we additionally treated fibroblasts and melanoma cells with similar concentrations of IM for 24h. We found no biphasic effect in fibroblasts, since they were resistant to the highest concentration used (10 5 nM). Melanoma cells did not show a biphasic effect either, since they were almost unaffected at low concentrations, whereas viability was 50% decreased at the highest concentration used in the experiment (10 5 nM) (Suppl. Fig. 3A ). Furthermore, we analyzed the viability of the SCC13 cell line after 24h treatment with several concentrations of the tumor promoting tetradecanoyl phorbol acetate (TPA), a drug structurally related to the anti-cancer drug IM, both being phorbol esters and known potent PKC activators (22). This was done to investigate if the effect observed with IM was drug-specific. Unlike IM we did not detect any biphasic effect upon TPA treatment (Suppl. Fig. 3B ).
Gene expression analysis reveals involvement of PKC and MAPK signaling
To identify genes and signaling pathways mediating IM activity, we performed gene expression analysis on primary keratinocytes and patient-derived SCC cells treated for 24h with either DMSO or different concentrations of IM (1 nM, 100 nM, 10 4 nM). In concordance with the results from the viability and proliferation assays, most genes were differentially expressed in the presence of 100 nM IM ( Fig. 2A) .
Fewer changes were detected at a concentration of 10 4 nM while 1 nM of IM had almost no effect (Suppl. signaling in SCC cells (Suppl. Fig. 4C ).
To identify key mediators of the IM effect, we took the top 5 upregulated genes in SCC cells that were also upregulated in keratinocytes. DEFB4A, ZP4, IL13RA2, CCL5, and IL1R2 were thus selected. We did not focus on C15orf48, which was also was among the top 5 upregulated genes, since we were interested in genes that are upregulated in both healthy and cancerous keratinocytes and C15orf48 was only found to be upregulated in SCC cells. Furthermore, we could not confirm the upregulation of C15orf48 in SCC tissue (data not shown). From literature research, we found DEFB4A, IL1R2 and IL13RA2 to be the most interesting ones. IL1R2 and IL13RA2 are decoy receptors that were thought to have no signaling function.
However, a recent paper demonstrated a signaling ability of IL13RA2 (23). Additionally, IL13AR2 was reported to slow down or even prevent tumor growth in mice when overexpressed in pancreatic or breast cancer cells (24). Furthermore, IL1β was shown to enhance proliferation of oral keratinocytes (25) and therefore the upregulation of its decoy receptor by IM may play a crucial role in the mechanism of action of IM. DEFB4A was shown to be differentially expressed in SCC (26). We then confirmed the upregulation of these genes by qPCR in keratinocytes, patient-derived SCC cells, two SCC cell lines, human epidermis and human SCC explants after 24h of IM treatment. We found IL1R2 and IL13RA2 consistently and significantly upregulated in all tested cell types and explant tissues after treatment with IM, while DEFB4A upregulation could not be confirmed in SCC cell lines and SCC explants (Suppl. Fig. 4D , Suppl. Tab. 1).
PKCδ plays a fundamental role in the mechanism of action of ingenol mebutate
As our pathway analysis agreed with earlier studies (16, 22) that indicated a role for PKC signaling following IM exposure, we further investigated this pathway as a possible mechanism of action in the loss of epithelial cell viability and proliferation. We incubated primary keratinocytes, patient-derived SCC cells and the SCC13 cell line with 100 nM IM for up to 45 minutes and found PKCδ to be highly phosphorylated in the hinge region (Y311) in all cell types while PKCα is not phosphorylated (Fig. 3A) . Y311 was previously reported to be required for PKCδ activation and furthermore enhances autophosphorylation of PKCδ on T505 (27). Accordingly, we found the activation loop (T505) of PKCδ to be more phosphorylated in all three cell types after 24h drug treatment, whereas this phosphorylation could be blocked by the PKC inhibitor AEB071 (Fig. 3B) . Although PKCδ can function without being phosphorylated at T505, this phosphorylation increases the catalytic activity of PKCδ (27). Furthermore, T505 phosphorylation influences the substrate specifity of PCKδ and is essential for the activation of the AP1 family of transcription factors (28).
To further investigate the role of PKCδ, we used IM alone or in combination with the PKC inhibitor AEB071 and measured cell viability of primary keratinocytes, SCC patient cells and the SCC13 cell line after 24h of treatment. We found cell viability to be partially rescued by PKC inhibition when treated with IM ( Fig. 3C ). Since the PKC inhibitor is not entirely specific for single isoforms, we further validated the role of PKCδ using siRNA to knock-down PKCδ in SCC13 cells followed by analysis of cell viability after 24h IM treatment. Similar to our findings with the PKC inhibitor, we detected a rescue of cell viability upon IM treatment when PKCδ was knocked down. A knock-down PKCα followed by IM treatment led only to a partial rescue, while PKCδ knock-down could rescue the IM-treated cells completely (Fig. 3D ).
ERK is activated by ingenol mebutate treatment in a PKC-dependent manner and mediates IMdependent effects on cell viability
Besides PKC signaling, our pathway analysis suggested ERK1/2 to be involved in mediating the effect of IM. To confirm this and to exclude other pathways involved in MAPK signaling (e.g. p38, JNK) we performed a phosphorylation array experiment with primary keratinocytes and SCC cells from three different donors and found ERK to be phosphorylated upon IM treatment, while other pathways of MAPK signaling (p38 and JNK) showed no or only weak phosphorylation (Suppl. (Fig. 4E) . Taken together these results indicate that ERK is rapidly phosphorylated by IM in a PKC-dependent manner upon drug treatment. To further investigate these pathways in the mechanism of action of IM we analyzed the viability of primary keratinocytes, patient-derived SCC cells and the SCC13 cell line after 24h treatment with either the drug alone or in combination with the ERK inhibitor (SCH772984) or the MEK inhibitor (GSK1120212B). As seen in previous experiments, cell viability dropped below 50% upon IM treatment. However, viability was partially rescued when cells were treated in combination with the MEK or ERK inhibitor but not in combination with the JNK inhibitor SP600125 or the p38 inhibitor SB203580 (Fig. 4F ).
IL1R2 and IL13RA2 partially mediate the mechanism of action of ingenol mebutate in SCC
To further investigate the role of IL1R2 and IL13RA2, we first confirmed their upregulation upon 24h IM treatment in keratinocytes, patient-derived SCC cells, the SCC12 and SCC13 cell lines and epidermis from human explants by qPCR (Suppl. Fig. 4D ). C15orf48 was not further investigated due to the lack of a Since we saw an upregulation of IL1R2 and IL13RA2 after 24h of treatment, we performed time course experiments in primary keratinocytes and epidermis from human skin explants to better define the timescale of gene regulation. We found both genes to be upregulated after 2-6h of treatment (Suppl. Fig.   6 ).
Furthermore we treated cells with IM alone or in combination with the PKC-, the MEK-or the ERK inhibitor respectively and found that the drug-dependent upregulation of both genes was partially abolished. IM in combination with JNK inhibition or p38 inhibition had almost no repressive effect on the expression of the two genes (Fig. 5A) . Additionally we knocked down PKCδ by siRNA, which also prevented the drugdependent upregulation of IL1R2 and IL13RA2 mRNA (Fig. 5B) . To find out whether IL1R2 or IL13RA2 play an essential role in the mechanism of action IM, we knocked down these two genes with siRNA and analyzed cell viability upon drug treatment. Interestingly, both IL1R2 and IL13RA2 knock down partially rescued the viability of drug-treated SCC13 cells (Fig. 5C ). 
Discussion
Ingenol mebutate (IM) is approved for the topical treatment of actinic keratosis (AK), the precursor of squamous cell carcinoma (SCC). However, its mechanism of action is not completely understood. Several studies investigated IM in the context of different cancers (15-17) and suggest a role of the innate immune system (14) but there is only one study that focuses on the effect on the actual target, the malignant keratinocytes (18). While that study used high IM concentrations (100-400 µM) and short incubation times, leading to cytotoxicity involving mitochondrial network disruption, we investigated the mechanism of action of IM in healthy keratinocytes, SCC cells and skin explants at lower concentrations (100 nM) and up to 72h. We showed that IM induced a direct effect on viability and proliferation on cells of different origin.
Previous studies on different mouse and human cancer cell lines, like melanoma or breast carcinoma, determined the lethal dose (LD90) of IM for these cells to be between 180 and 220 μM after 24h (13). other reports (16), we found fibroblasts to be relatively resistant to IM while melanoma cells were affected, but at higher concentrations than the keratinocytes. In contrast to melanoma cells and fibroblasts, we found a biphasic effect on viability and proliferation on keratinocytes and SCC cells. This determines that IM induces cell death in two ways, depending on concentration and cell type. Furthermore, our results on SCC13 cells indicated that the biphasic effect was IM-specific as compared to another PKC activator, TPA. Our microarray performed with various IM concentrations showed the highest number of genes differentially expressed at 100 nM, whereas effects were less pronounced at lower and higher concentrations, consistent with the impact of 100 nM IM on cell viability and proliferation. This pronounced effect at 100 nM again points to the existence of two different concentration-dependent mechanisms of action for IM, whereas the highest concentration used leads to cell death due to direct cytotoxicity. The lower concentration of 100 nM however, may trigger intracellular pathways that lead to the reduction of cell viability. These potential signaling pathways were subject to our further investigations. 
